drugset / Trial / NCT04545944

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

NCT04545944

Phase 1 Completed 20 enrolled Phathom Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To determine the time-dependent inhibition potential of repeated doses of oral vonoprazan on the pharmacokinetics (PK) of a single oral dose of midazolam, a sensitive cytochrome P450 3A4 (CYP3A4) substrate, in healthy participants.

Timeline

Start
2020-09-15
Primary completion
2020-11-13
Completion
2020-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 2 mg Oral
Subject Vonoprazan Other / unclassified 20 mg Oral

Indications

No indication recorded.